Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Catonsville, Maryland Clinical Trials

A listing of Catonsville, Maryland clinical trials actively recruiting patient volunteers.

RESULTS

Found (63) clinical trials

Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer

This is a single-center, single arm, open-label phase II study evaluating the safety, anti-tumor effect, and immunogenicity of neoadjuvant Dupixent given prior to radical prostatectomy in men with high-risk localized prostate cancer (this trial will enroll men with at least high risk prostate cancer defined by NCCN Guidelines Version 2.2017 ...

Phase

0.0 miles

Learn More »

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

This is a blinded and placebo-controlled study of topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with increased risk for cardiovascular (CV) disease.

Phase

2.52 miles

Learn More »

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

PRIMARY OBJECTIVES: I. To determine whether stereotactic body radiation therapy (SBRT) can be shown to be superior to hypofractionated intensity-modulated radiation therapy (IMRT) in terms of genitourinary (GU) and gastrointestinal (GI) toxicity by having fewer patients that experience a minimal important decline (MID) in urinary irritation/obstructive and bowel Health Related ...

Phase

2.52 miles

Learn More »

BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER

PRIMARY OBJECTIVES: I. To determine whether, in men with post-prostatectomy PSA recurrences, salvage radiation (SRT) with enhanced anti-androgen therapy with apalutamide will improve biochemical progression-free survival (bPFS) compared to SRT alone. SECONDARY OBJECTIVES: I. To assess whether molecular stratification by the PAM50 gene expression clustering will identify subsets of prostate ...

Phase

2.73 miles

Learn More »

A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Phase

6.25 miles

Learn More »

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

Patients with PSMA positive scans will be randomized in a 2:1 ratio to receive either 177Lu-PSMA-617 plus best supportive/best standard of care or to receive best supportive/best standard of care only. Best supportive/best standard of care will be determined by the treating physician/investigator but will exclude investigational agents, cytotoxic chemotherapy, ...

Phase

6.25 miles

Learn More »

Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

The purpose of this study is to evaluate the effectiveness of ProstAtak immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to ...

Phase

6.25 miles

Learn More »

Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA

PRIMARY OBJECTIVES: I. To compare the detection of clinically significant prostate cancer (CSPCa) in Arm 1 versus Arm 2. II. To compare between African American (AA) and white men the probability of developing CSPCa within three years of initial biopsy at the start of the study. SECONDARY OBJECTIVES: I. To ...

Phase N/A

6.25 miles

Learn More »

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

This is a two-arm, open label Phase 1b/2 study with an oral administration of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone in male patients with metastatic Castration Resistant Prostate Cancer. This study is designed to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) based on ...

Phase

6.25 miles

Learn More »

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone.

Phase

6.25 miles

Learn More »